Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Interest Expenses (2021 - 2025)

Historic Interest Expenses for Fennec Pharmaceuticals (FENC) over the last 10 years, with Q3 2025 value amounting to $586000.0.

  • Fennec Pharmaceuticals' Interest Expenses fell 4282.93% to $586000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 3185.66%. This contributed to the annual value of $4.1 million for FY2024, which is 1988.8% up from last year.
  • As of Q3 2025, Fennec Pharmaceuticals' Interest Expenses stood at $586000.0, which was down 4282.93% from $594000.0 recorded in Q2 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' Interest Expenses peaked at $1.0 million during Q2 2024, and registered a low of $4000.0 during Q1 2021.
  • Over the past 5 years, Fennec Pharmaceuticals' median Interest Expenses value was $696000.0 (recorded in 2023), while the average stood at $580611.1.
  • Its Interest Expenses has fluctuated over the past 5 years, first surged by 135000.0% in 2022, then tumbled by 4310.34% in 2025.
  • Quarter analysis of 5 years shows Fennec Pharmaceuticals' Interest Expenses stood at $55000.0 in 2021, then surged by 1561.82% to $914000.0 in 2022, then rose by 0.11% to $915000.0 in 2023, then rose by 5.57% to $966000.0 in 2024, then crashed by 39.34% to $586000.0 in 2025.
  • Its Interest Expenses stands at $586000.0 for Q3 2025, versus $594000.0 for Q2 2025 and $592000.0 for Q1 2025.